Feng-Lan Ge (h-index 0, 0 citations, 3 papers on clinical Chinese medicine topics) is almost certainly a novel/early-career author, and critically, none of the supplied research records can be confidently attributed to this author β they span materials chemistry, virology, single-cell genomics, and nephrology, fields unrelated to the author's three listed clinical/TCM papers. A meaningful scientific-strength review is therefore not possible without better author disambiguation.
The author record identifies Feng-Lan Ge with an h-index of 0, 0 total citations, and 3 papers: (1) Shenfu injection for chronic congestive heart failure, (2) postsurgical gastroparesis after subtotal gastrectomy, and (3) a hollow solubility small-cavity anastomosis technique. No affiliations are recorded. These are clinical/TCM-adjacent topics with no apparent connection to the research records supplied in this query.
The supplied research records (breast-cancer immunosensors, 5β²-tRF-GlyGCC CRC biomarker, virus-human PPI phenotype prediction, MDS/AML fucosylation, nickelate resistive switching, Musaceae genomics, HIV single-cell multiomics, lupus nephritis autoantibodies, copper GWAS/MR, Ru/Bi2Te3 thermoelectrics, medaka CRISPR, and others) span entirely different disciplines from Feng-Lan Ge's apparent clinical/TCM focus. None of the author lists in these records cite this individual. No scientific-strength conclusion can be drawn from this evidence corpus about this author.
To meaningfully review Feng-Lan Ge's scientific strength, we would need: (i) ORCID-linked author disambiguation, (ii) full text of the three listed papers (Shenfu injection, gastroparesis, anastomosis technique) to evaluate methodology, sample sizes, controls, and reproducibility, and (iii) confirmation of whether any of the supplied research records share an author ID with this profile. Without this, any further judgment would be confabulation.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.